Editorially Independent Content, Financially Supported by
Do lesion type and size influence outcomes in patients with wet age-related macular degeneration (AMD)? Nathan C. Steinle, MD, addresses this question in light of integrated data from the VIEW 1 and VIEW 2 post hoc analysis, which looked at lesion type and size across anti-VEGF therapy over 1 year. He suggests that perhaps it’s time to look at fluorescein angiography again to better characterize the long-term visual potential of patients.
Age-Related Macular Degeneration • Anti-VEGF • fluorescein angiography, FA